ВЛИЯНИЕ ТЕРАПИИ АТОРВАСТАТИНОМ НА КЛИНИЧЕСКОЕ ТЕЧЕНИЕ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ НЕИШЕМИЧЕСКОГО ГЕНЕЗА

Sergey Grishaev; Alexander  Filippov; Obrezan Andrey; Mikhail  Deriugin; Boris  Pomogaibo

doi:10.21638/11701/spbu11.2016.402

Authors

Sergey Grishaev Military Medical Academy named aft er S. M. Kirov, 6, ul. Akademika Lebedeva, St. Petersburg, 194044, Russian Federation
Alexander Filippov St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Mikhail Deriugin St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Boris Pomogaibo 413-Military Hospital, 81, prosp. Marshala Zhukova, Volgograd, 400107, Russian Federation

DOI:

https://doi.org/10.21638/11701/spbu11.2016.402

Abstract

Th e eff ect of 24 weeks of atorvastatin treatment in addition to the basic therapy was studied in 52 patients
suff ering from chronic myocarditis with heart failure (NYHA classes I–II with preserved ejection fraction). It is shown that the use of atorvastatin in a daily dose of 5–20 mg leads to reduced activity of immune infl ammation and is accompanied by positive dynamics of clinical symptoms. Refs 10. Figs 2. Tables 2.

Keywords:

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), chronic myocarditis, heart failure with preserved ejection fraction

Downloads

Download data is not yet available.

References

Литература

Рекомендации ЕОК/ЕОА по лечению дислипидемий // Рациональная фармакотерапия в кардиологии. 2012. Приложение 1. С. 1–63.

Tavazzi L., Maggioni A. P., Marchioli R., Barlera S., Franzosi M. G., Latini R., Lucci D., Nicolosi G. L.,Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet. 2008. Vol. 372. Р.1231–1239.

Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J. V., Waagstein F.,Wedel H., Wessman P., Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics // Eur. J. Heart Fail.2005. Vol. 7 (6). P. 1059–1069.

Рекомендации ЕОК по диагностике и лечению острой и хронической сердечной недостаточности // Российский кардиологический журнал. 2012. № 4 (102). Приложение 3. С. 1–68.

Wang J. Q., Wu G. R., Wang Z., Dai X. P., Li X. R. Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies // Heart Lung Circ. 2014. Vol. 23 (2). P. 105–113.

Бобров Л. Л., Гайворонская В. В., Куликов А. Н., Обрезан А. Г., Филиппов А. Е., Щербак Ю. А. Клиническая фармакология и фармакотерапия внутренних болезней. СПб., 2000. 365 c.

Van der Harst P., de Boer R. A. Challenges for the Basis of Practice. Statins in the Treatment of Heart Failure // Circ. Heart Fail. 2010. Vol. 3. P. 462–464.

Гришаев С. Л., Филиппов А. Е., Гладышева Э. В., Солнцев В. Н., Шуленин К. С., Кутелев Г. Г., Малышева О. С., Улятовский В. А., Захарова А. И. Опыт применения статинов у больных с хроническим миокардитом и сердечной недостаточностью с сохранной фракцией выброса // Вестник Российской военно-медицинской академии. 2015. № 3 (51). С. 58–61.

Косарев М. М., Обрезан А. Г., Стрельников А. А., Гурьянова А. В. Современные принципы диагностики хронической сердечной недостаточности // Клиническая медицина. 2011. Т. 89 (4). С. 8–13.

Smith D. G., Leslie S. J., Szucs T. D., McBride S., Campbell L. M., Calvo C., Lecerf J. M., Fellin R. Cost of treating to a modifi ed European Atherosclerosis Society LDL-C target. Comparson of atorvastatin with fluvastatin, pravastatin and simvastatin. (Treat-to-Target Study) // Clin. Drug Invest. 1999. Vol. 17. P. 185–193.

References

Rekomendatsii EOK/EOA po lecheniiu dislipidemii // [The recommendations of the ESC/EAS for the management of dyslipidemias]. Ratsional’naia Farmakoterapiia v Kardiologii [Rational Pharmacotherapy in Cardiology], 2012, appendix 1, pp. 1–63. (In Russian)

Tavazzi L., Maggioni A. P., Marchioli R., Barlera S., Franzosi M. G., Latini R., Lucci D., Nicolosi G. L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 2008, vol. 372, pp. 1231–1239.

Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J. V., Waagstein F., Wedel H., Wessman P., Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail.,2005, vol. 7 (6), pp. 1059–1069.

Rekomendatsii EOK po diagnostike i lecheniiu ostroi i khronicheskoi serdechnoi nedostatochnosti [ESC Guidelines for the diagnosis and treatment of acute and chronic Heart Failure]. Rossiiskii kardiologicheskii zhurnal [Russion Journal of cardiology], 2012, no. 4 (102), appendix 3, pp. 1–68. (In Russian)

Wang J. Q., Wu G. R., Wang Z., Dai X. P., Li X. R. Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies. Heart Lung Circ., 2014, vol. 23 (2),pp. 105–113.

Bobrov L. L., Gayvoronskaya V. V., Kulikov A. N., Obrezan A. G., Filippov A. E., Scherbak Yu. A.Klinicheskaia farmakologiia i farmakoterapiia vnutrennikh boleznei [Clinical pharmacology and pharmacotherapy of internal diseases]. St. Petersburg, 2000, 365 p. (In Russian)

Van der Harst P., de Boer R. A. Challenges for the Basis of Practice. Statins in the Treatment of Heart Failure. Circ. Heart Fail., 2010, vol. 3, pp. 462–464.

Grishaev S. L., Filippov A. E., Gladyisheva E. V., Solntsev V. N., Shulenin K. S., Kutelev G. G., Malyisheva O. S., Ulyatovskiy V. A., Zaharova A. I. Opyt primeneniia statinov u bol’nykh s khronicheskim miokarditom i serdechnoi nedostatochnost’iu s sokhrannoi fraktsiei vybrosa [Experience of the use of statins in patients with chronic myocarditis and heart failure with preserved ejection fraction]. Vestnik Rossiiskoi voenno-meditsinskoi akademii [Vestnik of Russian military medical Academy], 2015, no. 3 (51), pp.58–61. (In Russian)

Kosarev M. M., Obrezan A. G., Strelnikov A. A., Guryanova A. V. Sovremennye printsipy diagnostiki khronicheskoi serdechnoi nedostatochnosti [Modern principles of diagnostics of chronic heart failure].Klinicheskaia meditsina [Clinical medicine], 2011, vol. 89 (4), pp. 8–13. (In Russian)

Smith D. G., Leslie S. J., Szucs T. D., McBride S., Campbell L. M., Calvo C., Lecerf J. M., Fellin R. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparson of atorvastatin with fluvastatin, pravastatin and simvastatin (Treat-to-Target Study). Clin. Drug Invest., 1999, vol. 17, pp.185–193.